Alnylam Pharmaceuticals Inc

ALNY has failed to sustain downside control and has entered a structural repair phase marked by a Bullish Pivot Point and ongoing Lockout Rally dynamics. Price is tightly tracking the rising 9- and 20-day EMAs, offering a favorable buy-on-dip zone. Medium-term continuation patterns (higher highs and lows) support bullish participation, while the long-term downtrend under the 200-day SMA remains an overarching risk.

• ↑Q1 2026 revenue $1.0B, up 121% YoY with $910M from TTR
• ↑Amvuttra holds ~80% of new TTR prescriptions and 90% patient adherence
• ↓Valuation implies high expectations, risking downside if growth slows